http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#Head
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#assertion
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#provenance
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#pubinfo
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#assertion
http://purl.obolibrary.org/obo/DOID_2089
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_2089
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00969
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#association
http://www.w3.org/2000/01/rdf-schema#label
"Do not initiate in patients with constipation ( 4.1 History of chronic or severe constipation or sequelae from constipation; intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions; ischemic colitis; impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; Crohn's disease or ulcerative colitis; diverticulitis; severe hepatic impairment ( 4.2 Concomitant use of fluvoxamine ( 4.3 Alosetron hydrochloride tablets should not be initiated [see Warnings and Precautions ( 5.1 Alosetron hydrochloride tablets are contraindicated in patients with a history of the following: chronic or severe constipation or sequelae from constipation intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions ischemic colitis, impaired intestinal circulation, thrombophlebitis, or hypercoagulable state Crohn's disease or ulcerative colitis diverticulitis severe hepatic impairment Concomitant administration of alosetron hydrochloride tablets with fluvoxamine is contraindicated. Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1"
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB00969
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#provenance
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#pubinfo
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#sig
http://purl.org/nanopub/x/hasSignature
LnC3Emo87wUNfcb0vhs1TD0thVmLqipYJ87sKmsfDwzY82hqp+XGUmTeamNruYc6kgpS/azVEIg0Fp3ncUOtpiiCWMRk0Qh4Pz1ZCsBb9F7MqpILtS76mETqoG2Am7LzMaA85GkVjT86Lo4JW9NKigf6udU9Nk8GZZ9BBDuU1W0=
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg
http://purl.org/dc/terms/created
2021-08-23T18:51:56.157+02:00
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY